His scientific interests lie mostly in Surgery, Internal medicine, Carcinoma, Lung cancer and Cancer. His research brings together the fields of Anesthesia and Surgery. His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Oncology.
His Carcinoma study combines topics in areas such as Respiratory disease and Metastasis. His Lung cancer research incorporates themes from Thoracotomy and Radiology. His studies in Cancer integrate themes in fields like Antigen and Pathology.
Nasser K. Altorki mostly deals with Surgery, Lung cancer, Internal medicine, Cancer and Oncology. Nasser K. Altorki has included themes like Esophagectomy and Carcinoma in his Surgery study. The concepts of his Lung cancer study are interwoven with issues in Cancer research, Lung, Wedge resection and Radiology.
The various areas that Nasser K. Altorki examines in his Cancer research study include Carcinogenesis, Cancer cell, Metastasis and Immunology. In the field of Internal medicine, his study on Esophageal cancer, Adenocarcinoma and Chemotherapy overlaps with subjects such as In patient. His Cancer study frequently involves adjacent topics like Antigen.
Nasser K. Altorki focuses on Internal medicine, Lung cancer, Surgery, Oncology and Cancer. His work on Esophageal cancer, Cohort and Adenocarcinoma as part of his general Internal medicine study is frequently connected to In patient, thereby bridging the divide between different branches of science. The Adenocarcinoma study combines topics in areas such as Lung and Pathology.
His research integrates issues of KRAS, Cancer research, Lymphadenectomy and Radiology in his study of Lung cancer. His biological study deals with issues like Metastasis, which deal with fields such as Angiogenesis and Cell. His research in Oncology intersects with topics in Neoadjuvant therapy, Breast cancer and Chemotherapy, Adjuvant therapy.
Nasser K. Altorki spends much of his time researching Lung cancer, Surgery, Internal medicine, Pneumonectomy and Cancer research. As part of the same scientific family, Nasser K. Altorki usually focuses on Lung cancer, concentrating on Carcinoma and intersecting with T-stage and Survival analysis. While the research belongs to areas of Surgery, he spends his time largely on the problem of Lymphadenectomy, intersecting his research to questions surrounding Dissection.
His Internal medicine research incorporates elements of Gastroenterology and Oncology. His Cancer research research is multidisciplinary, incorporating elements of T cell, Immune system, Metastasis and Effector. His work focuses on many connections between Retrospective cohort study and other disciplines, such as Stage, that overlap with his field of interest in Propensity score matching.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Rosandra N. Kaplan;Rebecca D. Riba;Stergios Zacharoulis;Anna H. Bramley.
Early Lung Cancer Action Project: overall design and findings from baseline screening
Claudia I Henschke;Dorothy I McCauley;David F Yankelevitz;David P Naidich.
The Lancet (1999)
Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance
Kari R Fischer;Anna Durrans;Sharrell Lee;Jianting Sheng.
Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer.
Andrew J Dannenberg;Nasser K Altorki;Jay O Boyle;Chau Dang.
Lancet Oncology (2001)
Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: A propensity-matched analysis from the STS database
Subroto Paul;Nasser K. Altorki;Shubin Sheng;Paul C. Lee.
The Journal of Thoracic and Cardiovascular Surgery (2010)
Early Lung Cancer Action Project : Initial findings on repeat screening
Claudia I. Henschke;David P. Naidich;David F. Yankelevitz;Georgeann McGuinness.
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses
Sacha Gnjatic;Djordje Atanackovic;Elke Jäger;Mitsutoshi Matsuo.
Proceedings of the National Academy of Sciences of the United States of America (2003)
Immunohistochemical analysis of NY‐ESO‐1 antigen expression in normal and malignant human tissues
Achim A. Jungbluth;Yao-Tseng Chen;Elisabeth Stockert;Klaus J. Busam.
International Journal of Cancer (2001)
The Number of Lymph Nodes Removed Predicts Survival in Esophageal Cancer: An International Study on the Impact of Extent of Surgical Resection
Christian G Peyre;Jeffrey A Hagen;Steven R DeMeester;Nasser K Altorki.
Annals of Surgery (2008)
Inhibition of cyclooxygenase-2 gene expression by p53.
Kotha Subbaramaiah;Nasser Altorki;Wen Jing Chung;Juan R. Mestre.
Journal of Biological Chemistry (1999)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: